Incidentally Detected Asymptomatic Cardiac Myxoma in a Patient With COVID-19

Shakerian, Behnam; Jebelli, Mohammad; Mandegar, Mohammad Hossein

doi:10.1177/11795476221083115

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there was no clear explanation as to the histology of this growth in comparison to septal tissue, biopsy results confirmed non-malignant pathology. A previously reported case highlights the onset of a cardiac myxoma in a patient with COVID-19 [ 19 ]. Considering that the patient’s signs and symptoms began to worsen following a COVID-19 infection, it is possible that COVID-19 in addition to the existing myxoma possibly contributed to disease progression and onset.…”

Section: Discussionmentioning

confidence: 99%

“…Considering that the patient’s signs and symptoms began to worsen following a COVID-19 infection, it is possible that COVID-19 in addition to the existing myxoma possibly contributed to disease progression and onset. Many myxomas will not cause symptoms and are often discovered when an imaging study is done for another reason [ 19 ]. Regardless of etiology, the removal of said myxoma was necessary to decrease acute and chronic risk of disease complications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Adult Onset Hypertrophic Cardiomyopathy (HCM) Not Detected by Echocardiogram: A Case Presentation

Elsouri,

Camacho Ramos,

Stepanek

et al. 2023

Cureus

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disease of the sarcomere protein. The age of diagnosis of HCM tends to be between the second to third decades of life. However, the recent occurrence of HCM in the fifth and sixth decades of life has been seen in an increasing number of cases. In all cases, a transthoracic echocardiogram (TTE) is considered the gold standard of imaging. Here, we present a case of a 54-year-old Caucasian male who presented to the emergency department (ED) with dyspnea while on vacation. An electrocardiogram (ECG) taken at the time did not suggest any abnormalities. After returning home, a stress test conducted indicated left anterior descending (LAD) artery stenosis. Following treatment, symptoms improved temporarily but eventually came back. Repeat ECGs and TTEs done over the next two years indicated grade II diastolic dysfunction and mild left ventricular hypertrophy, which led to changes in the medication regime. Nevertheless, his condition progressively deteriorated over time. Repeat appearances to the ED led to the utilization of magnetic resonance imaging (MRI) to assess cardiac morphology function and velocity flow. The results were consistent with HCM. This case presents a unique obstacle for the diagnosis of adult-onset HCM. The change made to his medication regimen seemingly aggravated the patients’ condition. This case highlights the need for further imaging, beyond the gold standard, in adult males with repeated complaints of dyspnea on exertion (DOE).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Adult Onset Hypertrophic Cardiomyopathy (HCM) Not Detected by Echocardiogram: A Case Presentation

Elsouri,

Camacho Ramos,

Stepanek

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…However, small tumors may have no clinical symptoms 14 , 16 , 17 and are often diagnosed after imaging tests for other reasons. 18 Some patients may experience symptoms such as shortness of breath, angina pectoris, syncope, dizziness, fatigue, cough, and fever. 19 , 20 Furthermore, several cases of emboli have been reported in patients with myxoma, and more systemic emboli have been reported due to the increased prevalence of these left‐sided primary cardiac tumors.…”

Section: Introductionmentioning

confidence: 99%

“…The main factors involved in the development and type of clinical manifestations of myxomas include their locations, sizes, and mobility. However, small tumors may have no clinical symptoms 14,16,17 and are often diagnosed after imaging tests for other reasons 18 . Some patients may experience symptoms such as shortness of breath, angina pectoris, syncope, dizziness, fatigue, cough, and fever 19,20 .…”

Section: Introductionmentioning

confidence: 99%

Diagnosis of the right atrial myxoma after treatment of COVID‐19: A case report

Jelodar

Mirzaei

Chenari

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message Atrial myxoma is a rare disease but has a broad clinical presentation and complication that involves several systems‐ heart, lungs, brain, and systemic. An interdisciplinary approach is very important to optimize the outcome in patients with atrial myxomas. A thorough examination by primary care providers is crucial. Then radiologists or cardiologists can help with imaging modalities that can help diagnose and characterize the tumor. Prior to surgical resection by cardiothoracic surgeons, patients need to be evaluated by pulmonologists, cardiologists, and anesthesiologists for preoperative risk stratifications. In patients with neurological complications, pulmonary complications, or infectious endocarditis, input from neurologists, hematologists, infectious disease specialists is essential for patient care. In case antiplatelet/anticoagulation therapy or antibiotic treatment is warranted, pharmacists can provide valuable recommendations. Abstract Myxoma is the most common benign cardiac primary tumor, occurring in the right atrium in only 15%–20% of cases. This disease is asymptomatic initially depending upon size of the tumor, and symptoms develop as the tumor spreads. Atrial myxomas are associated with a triad of complications, including obstruction, emboli, and constitutional symptoms (such as fever and weight loss). This regard, embolization of the pulmonary circulation system is a complication of right myxoma. The patient was a 40‐year‐old male who presented to the emergency department complaining of fever and confusion. He had been previously hospitalized due to COVID‐19 and treated with Remdesivir and plasmapheresis. He had tachycardia, tachypnea, thrombocytopenia, and increased liver enzymes. Chest imaging showed nodular lesions with necrotic areas and cavitary lesions in both lungs and the right atrium infected clot was seen in echocardiography. He was treated with intravenous antibiotics and finally underwent heart surgery due to the diagnosis of pulmonary septic embolism. The patient was finally diagnosed with right atrial myxoma according to heart mass histopathology. It is worth noting that the patient's thrombosis had already developed on the right atrial myxoma, which delayed the diagnosis in this patient. This thrombus formation was due to the hypercoagulability state of COVID‐19 and following the insertion of a central venous catheter to perform plasmapheresis as a complication of treatment. Special attention should be paid to thromboprophylaxis and the early diagnosis of intravascular and intracardiac thrombosis in COVID‐19 patients. Furthermore, the use of imaging modalities is recommended to differentiate thrombus from myxoma.

show abstract

COVID-19 mortality in a patient with left atrial myxoma

2023

HSI Journal

View full text Add to dashboard Cite

Individuals with comorbid conditions, particularly those with cardiovascular diseases, are at a higher risk of mortality due to COVID-19. Among primary cardiac tumours, atrial myxoma is the most commonly reported, accounting for 85% of all cases. Most tumours occur in the left atrium with an associated embolic phenomenon in 40to 50% of patients. In this case report, we describe a 35-year-old woman of West African descent who had a left atrial myxoma and was waiting for surgery. She presented with signs and symptoms of biventricular heart failure, and her severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) test results were negative. She deteriorated and died while being optimized medically before cardiac surgery. Postmortem confirmed a left atrial myxoma, myocardial infarction, bacterial endocarditis, congestive cardiac failure, COVID-19 pneumonia, as well as a positive real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) SARS-CoV-2 test on lung swabs. Though uncommon, cardiac myxomas may result in mortality if not managed promptly. COVID-19 may complicate the management of patients with atrial myxoma with mortality.

show abstract

Incidentally Detected Asymptomatic Cardiac Myxoma in a Patient With COVID-19

Cited by 4 publications

References 3 publications

Adult Onset Hypertrophic Cardiomyopathy (HCM) Not Detected by Echocardiogram: A Case Presentation

Adult Onset Hypertrophic Cardiomyopathy (HCM) Not Detected by Echocardiogram: A Case Presentation

Diagnosis of the right atrial myxoma after treatment of COVID‐19: A case report

COVID-19 mortality in a patient with left atrial myxoma

Contact Info

Product

Resources

About